This Month in JNM
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2024 Category: Nuclear Medicine Tags: This Month in JNM Source Type: research
Artificial Intelligence for PET and SPECT Image Enhancement
Nuclear medicine imaging modalities such as PET and SPECT are confounded by high noise levels and low spatial resolution, necessitating postreconstruction image enhancement to improve their quality and quantitative accuracy. Artificial intelligence (AI) models such as convolutional neural networks, U-Nets, and generative adversarial networks have shown promising outcomes in enhancing PET and SPECT images. This review article presents a comprehensive survey of state-of-the-art AI methods for PET and SPECT image enhancement and seeks to identify emerging trends in this field. We focus on recent breakthroughs in AI-based PET ...
Source: Journal of Nuclear Medicine - January 2, 2024 Category: Nuclear Medicine Authors: Balaji, V., Song, T.-A., Malekzadeh, M., Heidari, P., Dutta, J. Tags: State of the Art Source Type: research
Expanding the Mission and Influence of SNMMI: A Conversation Between Johannes Czernin and Virginia Pappas About Her Career in SNMMI Leadership
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2024 Category: Nuclear Medicine Authors: Pappas, V., Czernin, J. Tags: Discussions with Leaders Source Type: research
Reply to "Theranostics Is Not Radiotheranostics"
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Weber, W. A. Tags: REPLY Source Type: research
Theranostics Is Not Radiotheranostics
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Wei, W. Tags: Letters Source Type: research
Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Enke, J. S., Bundschuh, R. A., Wienand, G., Reitsam, N. G., Kircher, M., Pfob, C. H., Lapa, C., Dierks, A. Tags: Illustrated Post Source Type: research
One Hundred Years of the Tracer Principle
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Hoberuck, S., Zophel, K., Pomper, M. G., Rowe, S. P., Gafita, A. Tags: Special Contributions Source Type: research
Performance Characteristics of a New-Generation Digital Bismuth Germanium Oxide PET/CT System, Omni Legend 32, According to NEMA NU 2-2018 Standards
Conclusion: The Omni Legend 32 has class-leading sensitivity and count rates within the category of whole-body PET systems while maintaining spatial resolution broadly comparable to that of other current SiPM-based PET/CT systems. This combination of properties results in a very good image quality. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Yamagishi, S., Miwa, K., Kamitaki, S., Anraku, K., Sato, S., Yamao, T., Kubo, H., Miyaji, N., Oguchi, K. Tags: Basic Science Investigations Source Type: research
[18F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration
Conclusion: [18F]PI-2620 SUVr shows an intense and consistent signal in AD but lower-intensity, heterogeneous, and rapidly decreasing binding in patients with suspected FTLD. Further work is needed to delineate the substrate of [18F]PI-2620 binding and the usefulness of [18F]PI2620 SUVr quantification outside the AD continuum. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Blazhenets, G., Soleimani-Meigooni, D. N., Thomas, W., Mundada, N., Brendel, M., Vento, S., VandeVrede, L., Heuer, H. W., Ljubenkov, P., Rojas, J. C., Chen, M. K., Amuiri, A. N., Miller, Z., Gorno-Tempini, M. L., Miller, B. L., Rosen, H. J., Litvan, I., G Tags: Clinical Investigations Source Type: research
Clinical Characterization of [18F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy
Conclusion: [18F]T-008 is a suitable PET radiotracer for quantitatively analyzing CH24H in the human brain. Using [18F]T-008 and PET, we demonstrated that soticlestat was brain-penetrant and established target engagement by displacing [18F]T-008 in a dose-dependent manner in the brain. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Constantinescu, C. C., Brown, T., Wang, S., Yin, W., Barret, O., Jennings, D., Tauscher, J. Tags: Clinical Investigations Source Type: research
[123I]CC1: A PARP-Targeting, Auger Electron-Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
Conclusion: Taken together, these results show the potential of [123I]CC1 as a radioligand therapy for PARP-expressing cancers. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Chan, C. Y., Chen, Z., Guibbal, F., Dias, G., Destro, G., ONeill, E., Veal, M., Lau, D., Mosley, M., Wilson, T. C., Gouverneur, V., Cornelissen, B. Tags: Basic Science Investigations Source Type: research
Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy
Conclusion: Targeted radionuclide therapy can be combined with Gd-NPs to increase the therapeutic effect and reduce the injected activities. As Gd-NPs are already used in the clinic, this combination could be a new therapeutic approach for patients with ovarian peritoneal carcinomatosis. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Garcia-Prada, C. D., Carmes, L., Atis, S., Parach, A., Bertolet, A., Jarlier, M., Poty, S., Garcia, D. S., Shin, W.-G., Du Manoir, S., Schuemann, J., Tillement, O., Lux, F., Constanzo, J., Pouget, J.-P. Tags: FEATURED ARTICLE OF THE MONTH Source Type: research
Immuno-PET and Targeted {alpha}-Therapy Using Anti-Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
Conclusion: [89Zr]GPC1 mAb PET showed high tumoral uptake in the early phase after administration, and targeted α-therapy using [211At]GPC1 mAb showed tumor growth suppression. GPC1 is a promising target for future applications for the precise diagnosis of pancreatic ductal adenocarcinoma and GPC1-targeted theranostics. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Watabe, T., Kabayama, K., Naka, S., Yamamoto, R., Kaneda, K., Serada, S., Ooe, K., Toyoshima, A., Wang, Y., Haba, H., Kurimoto, K., Kobayashi, T., Shimosegawa, E., Tomiyama, N., Fukase, K., Naka, T. Tags: Basic Science Investigations Source Type: research
Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein {alpha}
Conclusion: [68Ga]Ga-DOTA-4AH29 and [131I]I-GMIB-4AH29 enable precise FAP-positive tumor detection in mice. Therapeutic [225Ac]Ac-DOTA-4AH29 and [131I]I-GMIB-4AH29 exhibit strong and sustained tumor targeting, resulting in dose-dependent therapeutic effects in FAP-positive tumor-bearing mice, albeit with kidney toxicity observed later for [225Ac]Ac-DOTA-4AH29. This study confirms the potential of radiolabeled sdAb 4AH29 as a radiotheranostic agent for FAP-positive cancers, warranting clinical evaluation. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Dekempeneer, Y., Massa, S., Santens, F., Navarro, L., Berdal, M., Lucero, M. M., Pombo Antunes, A. R., Lahoutte, T., Van Ginderachter, J. A., Devoogdt, N., DHuyvetter, M. Tags: Basic Science Investigations Source Type: research
Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics
Conclusion: The combination of OncoFAP-based radioligand therapeutics with concurrent targeting of interleukin 2 shows synergistic anticancer effects in the treatment of FAP-positive tumors. This experimental finding should be corroborated by future clinical studies. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Galbiati, A., Dorten, P., Gilardoni, E., Gierse, F., Bocci, M., Zana, A., Mock, J., Claesener, M., Cufe, J., Buther, F., Schafers, K., Hermann, S., Schafers, M., Neri, D., Cazzamalli, S., Backhaus, P. Tags: Basic Science Investigations Source Type: research
